Sort by
Refine Your Search
-
Listed
-
Employer
- Eindhoven University of Technology (TU/e)
- Erasmus University Rotterdam
- Leiden University
- Utrecht University
- Delft University of Technology (TU Delft)
- Leiden University; yesterday published
- Radboud University
- DIFFER
- Eindhoven University of Technology (TU/e); today published
- University of Groningen
- DIFFER; Eindhoven
- Delft University of Technology (TU Delft); today published
- Delft University of Technology (TU Delft); yesterday published
- Eindhoven University of Technology (TU/e); yesterday published
- University of Amsterdam (UvA)
- University of Twente
- University of Twente (UT)
- AMOLF
- ARCNL
- Delft University of Technology (TU Delft); Published yesterday
- Eindhoven University of Technology (TU/e); 4 Oct ’25 published
- Erasmus University Rotterdam (EUR)
- Erasmus University Rotterdam (EUR); yesterday published
- KNAW
- Leiden University; today published
- Maastricht University (UM)
- Maastricht University (UM); 26 Sep ’25 published
- Max Planck Institute for the Study of Crime, Security and Law; Published yesterday
- University Medical Center Utrecht (UMC Utrecht)
- University Medical Center Utrecht (UMC Utrecht); today published
- University Medical Centre Groningen (UMCG); today published
- University of Amsterdam (UvA); Published 21 Nov ’25
- University of Amsterdam (UvA); Published yesterday
- University of Amsterdam (UvA); yesterday published
- University of Groningen; 26 Sep ’25 published
- University of Groningen; Published 28 Nov ’25
- University of Groningen; Published yesterday
- University of Twente (UT); Published today
- Utrecht University; Utrecht
- Utrecht University; Published today
- Utrecht University; Published yesterday
- Utrecht University; today published
- Vrije Universiteit Amsterdam (VU)
- 33 more »
- « less
-
Field
-
Extracellular vesicles (EVs) are natural, biocompatible carriers with innate targeting abilities, making them promising drug delivery vehicles. However, as seen with most nanoparticle platforms
-
of researchers from different parts of the world. The cell as producer and target for pharmaceuticals is the main part of the research at CBP. Prof. Schmidt’s research group (http://schmidt-researchgroup.com
-
and identify novel actionable targets for drug development. You will work extensively with patient-derived FFPE material, which is readily available within our clinical network. You will optimise and
-
component-level specifications to system-level specifications. The two PhD positions will focus on the use of contracts for modular control system design, targeting the following: 1. Contract synthesis
-
modelling approach, and dynamic Bayesian Networks would be advantageous. Willingness to conduct research in a multi-national project team. Funding requirements: You cannot have resided in The Netherlands in
-
with process safety and security concepts, accident modelling approach, and dynamic Bayesian Networks would be advantageous. Willingness to conduct research in a multi-national project team. Funding
-
We are seeking a highly motivated and creative PhD and EngD candidate to join our research team. While this advertisement primarily targets a PhD position (a 4-year project), we also anticipate
-
microbubbles can map microvascular dynamics but is limited to assessing intravascular flow and structure. Nanobubbles, capable of penetrating the tumor microvasculature and targeting cancer-specific biomarkers
-
primary cancer tissues, organoids and clinical samples. A key aim is to connect molecular mechanisms to tumour biology and identify novel actionable targets for drug development. You will work extensively
-
)inflammatory disorders, and its writers and erasers are emerging as promising drug targets. Your job In this project, you will apply chemical proteomics strategies in cells and tissues to study the role and